Page Title
Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 49-60 of 212 studies
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 49-60 of 212 studies
-
Anti-InfectiveClosed to Enrollment
Tobramycin Inhalation Powder (TIP) in People with Cystic Fibrosis Extension Study , protocol number Novartis CTBM100C2401E1The purpose of this extension study is to collect additional safety data from patients taking TIP who have completed the core study "Tobramycin Inhalation Powder (TIP) in People with Cystic Fibrosis".
-
Age:
6 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
25 to 75%
-
Number of Visits:
8
-
Length of Participation:
48 weeks
-
-
Anti-InfectiveClosed to Enrollment
Inhaled Levofloxacin (MP-376) pediatric safety study , protocol number MPEX 206This study took place at multiple care centers across the U.S. It looked at the safety and tolerability of MP-376 Inhalation Solution, as well as how the body processes the drug, in children with CF.
-
Age:
6 Years to 16 Years
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
25 to 95%
-
Number of Visits:
6
-
Length of Participation:
35 days
-
-
Nutritional-GIClosed to Enrollment
Study to evaluate Creon in adults with cystic fibrosis or chronic pancreatitis , protocol number AbbVie M21-432This study will look at the symptoms of exocrine pancreatic insufficiency (EPI) in adults with cystic fibrosis or chronic pancreatitis treated with Creon with an alternate source of active drug. Creon is a drug approved to treat EPI.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
3
-
Length of Participation:
142 days
-
-
Nutritional-GIClosed to Enrollment
OPTION 2: Study of AzurRX MS1819 in enteric capsules in adults with cystic fibrosis and exocrine pancreatic insufficiency , protocol number AzurRX AZ-CF2002This study will look at the safety and effectiveness of the drug MS1819 in enteric capsules as a pancreatic enzyme replacement therapy (PERT).
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
30% or greater
-
Number of Visits:
10
-
Length of Participation:
8 weeks
-
-
ObservationalClosed to Enrollment
Observational study comparing home to office spirometry in children 6 years of age and older and adults with cystic fibrosis. , protocol number OUTREACH-OB-22This is an observational study and includes no experimental drugs or events. This study is comparing home to office measuring of lung function, height, and weight. The aim of the study is to know more about the accuracy of these measurements when they are obtained at home as compared to their being obtained in the clinic.
-
Age:
6 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
4
-
Length of Participation:
4 months
-
-
ObservationalClosed to Enrollment
HERO-2 , protocol number HERO2-OB-2This study will collect everyday observations that individuals with CF, who are taking the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor (Trikafta®), make in their daily lives over 12 months. Participants will use the Folia app to track their routine treatments, medication usage, and symptoms, and will answer validated patient-reported outcome questionnaires. Participants who are participating in the CF Patient Registry will have their Registry data linked to their Folia tracking data to assess the relationship between any medication changes and changes in lung function. This study will not provide or make any treatment recommendations, and there are no required study visits.
-
Age:
12 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
0
-
Length of Participation:
12 months
-
-
ObservationalClosed to Enrollment
Study to evaluate the effects of the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor in children (PROMISE Pediatric Cohort) , protocol number PROMISE-OB-18 - Pediatric CohortThis observational study will measure the effects of the triple-combination therapy, elexacaftor/tezacaftor/ivacaftor, in children with CF. These drugs are intended to help CFTR protein function closer to normal. This study will look at how treatment with the triple-combination therapy affects children with CF across many different aspects of the disease.
-
Age:
6 Years to 11 Years
-
Mutation(s):
Two Copies F508del or One Copy F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
8
-
Length of Participation:
4 years
-
-
ObservationalClosed to Enrollment
Study to evaluate the effects of the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor (PROMISE) , protocol number PROMISE-OB-18PROMISE is a postapproval, real-world, observational study to understand the effects of elexacaftor/tezacaftor/ivacaftor (ETI) in clinical use in the United States.
-
Age:
12 Years and Older
-
Mutation(s):
Two Copies F508del or One Copy F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
8
-
Length of Participation:
4 years
-
-
ObservationalClosed to Enrollment
GI symptoms observational study (GALAXY) , protocol number GALAXY-OB-18This study will collect information on gastrointestinal (GI) symptoms that people with CF experience.
-
Age:
2 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
1
-
Length of Participation:
29 days
-
-
ObservationalClosed to Enrollment
Phase 4 TOBI Podhaler observational study , protocol number Novartis CTBM100C2407This study is taking place at multiple care centers across the U.S. It will look at the effectiveness and long term safety of the TOBI Podhaler and other FDA-approved inhaled antipseudomonal drugs.
-
Age:
6 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
25 to 80%
-
Number of Visits:
22
-
Length of Participation:
60 months
-
-
ObservationalClosed to Enrollment
Porcine viral antibody point prevalence study in people with CF taking pancreatic enzymes , protocol number AbbVie JSPP-12-01This study is taking place at multiple care centers across the U.S. It will look at the prevalence of antibodies to hepatitis E virus (HEV) and other selected porcine viruses in people with cystic fibrosis who are receiving pancreatic enzyme replacement therapy (PERT).
-
Age:
2 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
1
-
Length of Participation:
1 days
-
-
ObservationalClosed to Enrollment
An Ocular Safety Study of Kalyedeco-Treated Children 11 Years of Age or Younger with CF , protocol number Vertex VX-770-115This trial is designed to evaluate the risk of cataracts (lens opacities) and describe the best corrected distance vision (with glasses/contacts for those who wear them) of children with Cystic Fibrosis who are 11 years of age or younger at the time of ivacaftor (Kalydeco) treatment initiation and are receiving or planning to receive commercially-available ivacaftor (Kalydeco) in the US.
-
Age:
6 Years to 11 Years
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
5
-
Length of Participation:
2 years
-
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More